FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...

aaSouth African Centre for Epidemiological Modelling and Analysis, Centre for Epidemic Response and Innovation, School for Data Science and Computational Thinking, Stellenbosch University, ...

Detailed price information for Dell Technologies Inc (DELL-N) from The Globe and Mail including charting and trades.